Scholarlink

<p>Primary hepatocellular carcinoma (HCC) is a prevalent malignancy in China, often diagnosed at intermediate to advanced stages, limiting the feasibility of curative surgical resection. Yttrium-90 selective internal radiation therapy (<sup>90</sup>Y-SIRT) has emerged as a novel treatment demonstrating potential for prolonging survival and inducing clinical remission in HCC patients. Its efficacy and safety have been progressively validated in clinical settings. This report describes a middle-aged male patient diagnosed with HCC accompanied by portal vein tumor thrombus. The treatment regimen comprised oral lenvatinib, intravenous sintilimab, and <sup>90</sup>Y-SIRT. Successful sequential surgery was performed 7 months after <sup>90</sup>Y-SIRT, and a 6-week follow-up showed no significant abnormalities. This case suggests that <sup>90</sup>Y-SIRT, combined with other therapies, may be effective for patients with intermediate to advanced stage HCC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Sequential surgery following Yttrium-90 resin microspheres combined with targeted therapy and immunotherapy for primary hepatocellular carcinoma: a case report

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月1日

查看全文
  • Fang-Yuan Hu,
  • Jun Li,
  • Mo-Yan Xiao,
  • Chang-Yong Chen,
  • Ke Ye,
  • Ge-Wen Zhang

摘要

Primary hepatocellular carcinoma (HCC) is a prevalent malignancy in China, often diagnosed at intermediate to advanced stages, limiting the feasibility of curative surgical resection. Yttrium-90 selective internal radiation therapy (90Y-SIRT) has emerged as a novel treatment demonstrating potential for prolonging survival and inducing clinical remission in HCC patients. Its efficacy and safety have been progressively validated in clinical settings. This report describes a middle-aged male patient diagnosed with HCC accompanied by portal vein tumor thrombus. The treatment regimen comprised oral lenvatinib, intravenous sintilimab, and 90Y-SIRT. Successful sequential surgery was performed 7 months after 90Y-SIRT, and a 6-week follow-up showed no significant abnormalities. This case suggests that 90Y-SIRT, combined with other therapies, may be effective for patients with intermediate to advanced stage HCC.